The schedule continues weekly to provide more access to physicians. Photo: Prati-Donaduzzi Press.
The evolution of Prati-Donaduzzi, located in Toledo, Paraná, is a constant. One of the pillars of this growth is the commitment to all people in the pharmaceutical sector. The new moment of the industry, in the area of Medical Prescription, also has the responsibility of bringing technical and scientific information to the physicians.
In line with this concept, the pharmaceutical company holds a series of continuing education meetings for physicians. Several editions have already been held and hundreds of professionals from different specialties participated. The schedule continues weekly to provide more access to physicians.
The meetings aim to provide an information environment and clarify issues and doubts about the Resolution of the Collegiate Board (RDC) 327/2019 of the National Health Regulatory Agency (Anvisa), which allowed the commercialization of Cannabis-based products in Brazil.
Prati-Donaduzzi’s Innovation and Clinical Research manager, Liberato Brum Júnior, who addresses regulatory aspects of Brazil and technical and scientific information on the first and only national product of Cannabidiol mediate the online meetings. Another person who is responsible for mediating the meetings is Dr. Daniela Bezerra, who is a Pediatric Neurologist with a specialization in Epileptology from ILAE. She shares clinical cases and prescription experiences with fellow physicians participating in the meetings.
“Events like these ones are essential to increase knowledge, since there are still many doubts and incorrect information about Cannabidiol in Brazil. It is also an opportunity to understand and clarify the needs of physicians”, says Liberato.
Central Nervous System
The pharmaceutical company from Paraná is renowned for the excellence and quality in the production of medicines in Brazil. At this new moment, it advances with the branded product line and is now highlighted among the medical class.
"Our commitment is also to contribute to the updating of professionals, bringing information on various issues, changes in legislation, presentation of clinical studies, among others", says the Director of Medical Prescription, Edilson Bianqui.
The launch of Cannabidiol Prati-Donaduzzi is the great leap in this new phase of the company. In addition to this product, the pharmaceutical industry plans to launch more than 22 new branded drugs, most of which are aimed at the Central Nervous System (CNS) and indicated to treat diseases such as epilepsy, Parkinson's, Alzheimer's, anxiety, depression, neuropathic pain, schizophrenia, autism, bipolarity and insomnia.